Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare

659 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ASND Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Ascendis

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$257.63

▲(25.24% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $257.63 with a high forecast of $307.00 and a low forecast of $220.00. The average price target represents a 25.24% change from the last price of $205.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","170":"$170","216":"$216","262":"$262","308":"$308"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":307,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$307.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":257.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$257.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$220.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,170,216,262,308],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,204.11,212.0246153846154,219.9392307692308,227.85384615384618,235.76846153846154,243.68307692307692,251.5976923076923,259.5123076923077,267.42692307692306,275.34153846153845,283.25615384615384,291.1707692307692,299.0853846153846,{"y":307,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,204.11,208.2269230769231,212.34384615384616,216.46076923076924,220.5776923076923,224.6946153846154,228.81153846153848,232.92846153846153,237.04538461538462,241.1623076923077,245.27923076923076,249.39615384615385,253.51307692307694,{"y":257.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,204.11,205.3323076923077,206.5546153846154,207.77692307692308,208.9992307692308,210.22153846153847,211.44384615384615,212.66615384615386,213.88846153846154,215.11076923076922,216.33307692307693,217.5553846153846,218.77769230769232,{"y":220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$307.00

Average Price Target$257.63

Lowest Price Target$220.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luca Issi

RBC Capital

$240

Buy

16.67%

Upside

Reiterated

10/24/25

RBC Capital Keeps Their Buy Rating on Ascendis Pharma (ASND)

Tazeen Ahmad

Bank of America Securities

$230→$242

Buy

17.64%

Upside

Reiterated

10/20/25

Ascendis Pharma's Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating

Martin Auster

Raymond James

$271

Buy

31.74%

Upside

Initiated

10/17/25

Ascendis Pharma initiated with a Strong Buy at Raymond JamesAscendis Pharma initiated with a Strong Buy at Raymond James

Derek Archila

Wells Fargo

$295→$297

Buy

44.38%

Upside

Reiterated

10/15/25

Analysts Are Bullish on These Healthcare Stocks: AptarGroup (ATR), Ascendis Pharma (ASND)Based on our assessment—and as shown in the rating changes table—the price target for ASND has been revised from $295 to $297.

Maxwell Skor

Morgan Stanley

$250

Buy

21.53%

Upside

Reiterated

10/13/25

Ascendis Pharma (ASND) Receives a Buy from Morgan StanleyASND.O Ascendis Pharma A/S Overweight 12,528 209.55 250.00 250.00 (6.16) (6.22) 1.18 1.19

Li Watsek

Cantor Fitzgerald

$203→$254

Buy

23.47%

Upside

Reiterated

10/12/25

Ascendis Pharma price target raised to $254 from $203 at Cantor FitzgeraldAscendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald

Jessica Fye

J.P. Morgan

$260→$264

Buy

28.34%

Upside

Reiterated

10/09/25

J.P. Morgan Sticks to Its Buy Rating for Ascendis Pharma (ASND)JPMorgan analyst Jessica Fye raised the price target on Ascendis Pharma (NASDAQ: ASND) to $264.00 (from $260.00) while maintaining a Overweight rating.

Yun Zhong

Wedbush

$220

Buy

6.95%

Upside

Reiterated

10/03/25

Ascendis Pharma's Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation

Joseph Schwartz

Leerink Partners

$225

Buy

9.38%

Upside

Reiterated

09/23/25

Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Eliana Merle

UBS

$307

Buy

49.24%

Upside

Reiterated

09/22/25

Ascendis Pharma's Market Leadership and Growth Potential in Chronic Hypoparathyroidism

Paul Choi

Goldman Sachs

$250

Buy

21.53%

Upside

Reiterated

09/05/25

Yaron Werber

TD Cowen

$194→$227

Buy

10.35%

Upside

Reiterated

08/08/25

Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating

Alex Thompson CFA

Stifel Nicolaus

$212→$254

Buy

23.47%

Upside

Reiterated

08/08/25

Stifel Nicolaus Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Gavin Clark-Gartner

Evercore ISI

$280→$285

Buy

38.54%

Upside

Reiterated

08/08/25

Evercore ISI Sticks to Its Buy Rating for Ascendis Pharma (ASND)

Leland Gershell

Oppenheimer

$224→$246

Buy

19.59%

Upside

Reiterated

08/08/25

Oppenheimer Remains a Buy on Ascendis Pharma (ASND)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luca Issi

RBC Capital

$240

Buy

16.67%

Upside

Reiterated

10/24/25

RBC Capital Keeps Their Buy Rating on Ascendis Pharma (ASND)

Tazeen Ahmad

Bank of America Securities

$230→$242

Buy

17.64%

Upside

Reiterated

10/20/25

Ascendis Pharma's Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating

Martin Auster

Raymond James

$271

Buy

31.74%

Upside

Initiated

10/17/25

Ascendis Pharma initiated with a Strong Buy at Raymond JamesAscendis Pharma initiated with a Strong Buy at Raymond James

Derek Archila

Wells Fargo

$295→$297

Buy

44.38%

Upside

Reiterated

10/15/25

Maxwell Skor

Morgan Stanley

$250

Buy

21.53%

Upside

Reiterated

10/13/25

Ascendis Pharma (ASND) Receives a Buy from Morgan StanleyASND.O Ascendis Pharma A/S Overweight 12,528 209.55 250.00 250.00 (6.16) (6.22) 1.18 1.19

Li Watsek

Cantor Fitzgerald

$203→$254

Buy

23.47%

Upside

Reiterated

10/12/25

Ascendis Pharma price target raised to $254 from $203 at Cantor FitzgeraldAscendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald

Jessica Fye

J.P. Morgan

$260→$264

Buy

28.34%

Upside

Reiterated

10/09/25

Yun Zhong

Wedbush

$220

Buy

6.95%

Upside

Reiterated

10/03/25

Ascendis Pharma's Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation

Joseph Schwartz

Leerink Partners

$225

Buy

9.38%

Upside

Reiterated

09/23/25

Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Eliana Merle

UBS

$307

Buy

49.24%

Upside

Reiterated

09/22/25

Ascendis Pharma's Market Leadership and Growth Potential in Chronic Hypoparathyroidism

Paul Choi

Goldman Sachs

$250

Buy

21.53%

Upside

Reiterated

09/05/25

Yaron Werber

TD Cowen

$194→$227

Buy

10.35%

Upside

Reiterated

08/08/25

Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating

Alex Thompson CFA

Stifel Nicolaus

$212→$254

Buy

23.47%

Upside

Reiterated

08/08/25

Stifel Nicolaus Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Gavin Clark-Gartner

Evercore ISI

$280→$285

Buy

38.54%

Upside

Reiterated

08/08/25

Evercore ISI Sticks to Its Buy Rating for Ascendis Pharma (ASND)

Leland Gershell

Oppenheimer

$224→$246

Buy

19.59%

Upside

Reiterated

08/08/25

Oppenheimer Remains a Buy on Ascendis Pharma (ASND)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

1 Month

xxx

Success Rate

22/30 ratings generated profit

Average Return

+3.90%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +3.90% per trade.

3 Months

xxx

Success Rate

20/26 ratings generated profit

Average Return

+11.15%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +11.15% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

28/32 ratings generated profit

Average Return

+28.96%

reiterated a buy rating 11 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +28.96% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+63.59%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +63.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ASND has received 37 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 257.63.

Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is -$0.28 with a range of -$1.10 to $0.31. The previous quarter’s EPS was -$0.95. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ASND has Preformed in-line its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $247.64M with a range of $227.98M to $277.83M. The previous quarter’s sales results were $179.27M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ASND has Preformed in-line its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 257.63.

What is ASND’s upside potential, based on the analysts’ average price target?

Ascendis Pharma has 25.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ASND a Buy, Sell or Hold?

Ascendis Pharma has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ascendis Pharma’s price target?

The average price target for Ascendis Pharma is 257.63. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $307.00 ,the lowest forecast is $220.00. The average price target represents 25.24% Increase from the current price of $205.71.

What do analysts say about Ascendis Pharma?

Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of ASND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ascendis Pharma (ASND) Stock Forecast & Price Target

ASND Analyst Ratings

ASND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ascendis Pharma

ASND Analyst Recommendation Trends

ASND Financial Forecast

ASND Earnings Forecast

ASND Sales Forecast

ASND Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts